New study tests powerful cholesterol drug right after heart attacks
NCT ID NCT04951856
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding evolocumab (Repatha) to standard care helps people who recently had a heart attack reach very low LDL cholesterol levels and avoid death or unplanned heart-related hospital stays. About 2,166 participants with STEMI or NSTEMI will be randomly assigned to evolocumab injections every two weeks or usual care. The trial is active but no longer recruiting, and results are expected to show if this approach is better than standard cholesterol management.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Evolocumab (Repatha), a cholesterol-lowering injection
What this could lead to
If it works, this could show that adding evolocumab right after a heart attack helps more people reach very low cholesterol goals and reduces the risk of death or heart-related hospital stays.
What could go wrong
This is a phase 4 trial, so the drug is already approved, but it may not prove a clear benefit over standard care. Side effects like injection-site reactions or muscle pain are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ST ELEVATION MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ACTION Group, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière (APHP), UPMC
Paris, 75013, France